Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.

International journal of cancer - 1 Apr 2017

Levingston Corinne A, Young M Rita I

Abstract excerpt

A carcinogen-induced premalignant oral lesion model that progresses to oral cancer was used to examine the impact of blocking PD-1 on cytokine expression and on progression of lesions to cancer. The results of this study show increased production of IL-2 and the inflammatory cytokines IL-6, IL-17 and TNF-α by spleen cells of lesion-bearing mice that were treated with PD-1 antibody for 1 week compared to cytokine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to CD4-Positive T-Lymphocytes
Share to Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mouth Neoplasms

Share to Precancerous Conditions

Share to Programmed Cell Death 1 Receptor

Share to Spleen

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 27914100
DOI: 10.1002/ijc.30543
PMCID: PMC5324681

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.PMID 27914100Read ↗

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.Semantic proximity Read ↗

Role of IL-23 signaling in the progression of premalignant oral lesions to cancer.Semantic proximity Read ↗

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapySemantic proximity Read ↗

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine.Semantic proximity Read ↗

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer modelSemantic proximity Read ↗

Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer.Semantic proximity Read ↗

A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitorsSemantic proximity Read ↗

Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.Semantic proximity Read ↗

Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma.Semantic proximity Read ↗

Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.